

THE VEEDA NEWSLETTER



Completing One Month of Veeda Lifesciences

A month of growth for Veeda Lifesciences—evolving, streamlining, and creating a cohesive brand experience at all touch points.

Inside Veeda Group: January 2025

From the CEO’s Desk

Veeda Voice

Industry Insider

Employee Spotlight

 info@veedalifesciences.com

 www.veedalifesciences.com



Excellence
In Everything

From the CEO's DESK



A Message from Dr. Mahesh Bhalgat, Group CEO & MD, Veeda Lifesciences

We are entering an incredible time as we take a step forward with a new identity—**Veeda Lifesciences**. This transformation reflects our transition from generics to innovation, from local to global, and from small molecules to biologics.

As a full-service CRO, we are committed to delivering execution capabilities across the world through a borderless approach. By leveraging real-world data, AI-driven patient matching, and a robust global trial network, we are addressing critical industry challenges—speed, diversity, and efficiency in clinical research—while maintaining compliance and exceptional quality.

At the heart of Veeda Lifesciences is our unwavering commitment to excellence, quality, and innovation in everything we do. We are now Veeda Lifesciences, and we believe in achieving excellence in everything.

Thank you.



info@veedalifesciences.com



www.veedalifesciences.com

PRESS RELEASE

Veeda Group rebrands to

Veeda Lifesciences

Check out our press release to learn more about our new brand identity

[Read Now!](#)



Veeda Lifesciences Unveils New Identity for Global Impact

In a transformative step, Veeda Group rebrands as Veeda Lifesciences, signifying its evolution into a comprehensive CRO-CDMO powerhouse. This bold new identity reflects its vision of innovation, excellence, and global leadership in lifesciences.

Experience the New Brand Identity of Veeda Lifesciences – Watch Now!

A month ago, we embraced a new identity—one that reflects our growth, innovation, and commitment to excellence. Watch our brand unveiling video to see how Veeda Lifesciences is evolving for the future!

DR. MAHESH BHALGAT
GROUP CEO & MD

where you start out

What's Next in Medicine: Podcast with Dr. Mahesh Bhalgat

Watch as our Group CEO and MD takes you behind the scenes of the global clinical trials landscape, the transformation of the industry over the last few decades, future of Veeda Lifesciences and more.



Our New Identity takes shape across our Global Offices

This is a step forward in aligning our vision with the needs of those we serve. We are working towards creating a cohesive experience at every touchpoint, ensuring consistency and connection across all interactions.



info@veedalifesciences.com



www.veedalifesciences.com



New licensing rules mandate compliance with Schedule TB for ASU nasal sprays for patient safety

The Union ministry of health has announced a significant amendment to the Drugs Rules, 1945, concerning Ayurvedic, Siddha, and Unani (ASU) nasal sprays...

[Read More](#)

Unauthorized use of NABL logo may lead to legal action: NABL clarifies

In a recent clarification, the National Accreditation Board for Testing and Calibration Laboratories (NABL) has reiterated its stance on the use of its logo and symbol, emphasizing strict adherence to established policies...

[Read More](#)

MoFAHD reconstitutes Committee for Control and Supervision of Experiments on Animals

The ministry of fisheries, animal husbandry and dairying (MoFAHD) has reconstituted the Committee for Control and Supervision of Experiments on Animals (CCSEA), substituting the prevailing Committee it formed in November, 2021...

[Read More](#)

AstraZeneca



AstraZeneca plans C\$820 million investment in Canada to advance growing global hub & clinical delivery

AstraZeneca, a global pharmaceutical company focused on developing life changing medicines, has announced a C\$820 million (US\$570 million) investment in Canada, creating more than 700 new scientific and high-skilled jobs, across all areas of the business...

[Read More](#)

Syngene

Syngene International in Q3 reports Rs. 944 crore revenues with 11% growth

Syngene International in its third quarter revenue from operations was up by 11 per cent year-on-year to Rs. 944 crore and increased sequentially by 6 per cent from the prior quarter. Reported profit after tax, after exceptional items, was up 18 per cent year-on-year to Rs. 131 crore...

[Read More](#)

Eikonizo
Therapeutics

Eikonizo Therapeutics secures equity investment from Novo Nordisk to advance its lead candidate EKZ-102

Eikonizo Therapeutics, a biopharmaceutical company dedicated to developing disease-modifying therapies to improve the lives of people impacted by neurodegenerative and cardiorenal diseases, announced that it has secured an undisclosed equity investment from Novo Nordisk through its Science2Medicine iNNvest initiative...

[Read More](#)

info@veedalifesciences.com



www.veedalifesciences.com



Immuneel Therapeutics launches Qartemi, India's first global CAR T-cell therapy for non-Hodgkin's lymphoma

In a significant step forward for India's cancer treatment, Immuneel Therapeutics has introduced Qartemi, country's first global CAR T-cell therapy for adult B-cell non-Hodgkin lymphoma (B-NHL)...

[Read More](#)



ImaginAb signs agreement to sell proprietary novel biologics technology platform to Telix Pharma

ImaginAb, Inc, a clinical stage, revenue-generating global biotechnology company developing the next generation of radiopharmaceutical and imaging agent products, announced that it has entered into an agreement to sell a pipeline of next-generation therapeutic candidates...

[Read More](#)



TuHURA Biosciences announces completion of merger transaction with Kintara Therapeutics

TuHURA Biosciences, a phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, has announced the completion of its previously announced merger with Kintara Therapeutics, Inc. (now known as TuHURA Biosciences, Inc.)..

[Read More](#)



Lundbeck to buy clinical-stage biopharma company, Longboard Pharmaceuticals for USD 2.6 billion

Under the terms of the agreement, Lundbeck will commence a tender offer for all outstanding shares of Longboard common stock, whereby Longboard shareholders will be offered a payment of USD 60.00 per share in cash...

[Read More](#)



Odisha soon to release exclusive pharma policy to make the state a pharmaceutical powerhouse

With an aim to make Odisha a pharmaceutical powerhouse in the eastern part of the country, the government of Odisha is preparing an exclusive pharma policy 2025 for the state...

[Read More](#)



Indian healthcare providers caution on risk of Mtb spread as US FDA issues guidance to reduce risk of transmission

Indian healthcare providers caution on risk of mycobacterium TB spread as US FDA issues guidance to reduce risk of transmission...

[Read More](#)



Employee SPOTLIGHT



James Brook, COO (Global Clinical Trials), on Veeda Lifesciences

Watch our COO, as he shares how Veeda Lifesciences connects Western and Eastern markets, leveraging a vast KOL network to deliver efficient, high-quality clinical trials across 26 geographies—all under one roof.

Watch Now!



Veeda Premier League 2024: Celebrating Sportsmanship, Diversity & Victory

Veeda Premier League 2024 was a thrilling celebration of teamwork, inclusivity, and excellence. With record-breaking performances, high engagement on CricHeroes, and inspiring leadership, the tournament brought employees together, reinforcing Veeda's core values. Congratulations to the champions—Power Hitters & Valkyries of Veeda!

Watch Now!



info@veedalifesciences.com




www.veedalifesciences.com

Contact Us

Global Offices

- India
- Greece
- Italy
- Ireland



Disclaimer: The information compiled and published in this newsletter has been sourced, collected, and derived from various resources that are publicly available on the web and relevant sites. This newsletter may contain references to third-party trademarks, logos, and brand names, which are the property of their respective owners. These trademarks, logos, and brand names are used for informational and reference purposes only and do not imply any endorsement, sponsorship, or affiliation with Veeda and/or its affiliates, subsidiary, group companies and stakeholders. Veeda makes no claims, promises, or guarantees about the accuracy, completeness, or adequacy of the contents of this newsletter and expressly disclaims liability for errors and omissions. The intent and objective of this newsletter are solely to disseminate scientific information for knowledge enhancement. The reproduction or transmission of any items covered in this newsletter beyond that allowed by fair use as defined in the copyright laws may require the written permission of the copyright owners, if any. Neither Veeda nor its employees or contractors make any warranties, expressed or implied, including but not limited to non-infringement of third-party rights, title, or the warranties of merchantability and fitness for a particular purpose concerning the content available in the newsletter. This is not a service provided by Veeda Clinical Research, and it does not assume responsibility for the accuracy of the information presented herein.

 info@veedalifesciences.com

 www.veedalifesciences.com



Excellence
In Everything